Xagena.net - Update in Medicine

Baricitinib has shown superiority to Adalimumab in improving signs and symptoms of rheumatoid arthritis

Results of RA-BEAM, a phase 3 study of Baricitinib, in patients with moderately-to-severely active rheumatoid arthritis were announced. The study met its primary objective of demonstrating superiorit ... read article

Humira, approved in Europe for children and adolescents from four years of age with severe chronic plaque psoriasis

The European Commission ( EC ) has granted marketing authorization for Humira ( Adalimumab ) for the treatment of severe chronic plaque psoriasis in children and adolescents from four years of age who ... read article

Humira for the treatment of pediatric patients with moderately to severely active Crohn’s disease, approved by FDA

The FDA ( Food and Drug Administration ) has approved Humira ( Adalimumab ) for reducing signs and symptoms, and achieving and maintaining clinical remission, in pediatric Crohn's disease patients 6 y ... read article

Humira for the treatment of pediatric patients with moderately to severely active Crohn's disease, approved by FDA

The FDA ( Food and Drug Administration ) has approved Humira ( Adalimumab ) for reducing signs and symptoms, and achieving and maintaining clinical remission, in pediatric Crohn's disease patients 6 y ... read article

Humira approved in the United States for polyarticular juvenile idiopathic arthritis indication in patients ages two and older

The FDA ( Food and Drug Administration ) has approved the extension of the Humira ( Adalimumab ) indication for moderately to severely active polyarticular juvenile idiopathic arthritis ( JIA ) t ... read article

FDA: orphan drug designation for Humira for the investigational treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis

The FDA ( Food and Drug Administration ) has granted Humira ( Adalimumab ) orphan drug designation for the treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectiou ... read article

Crohn's disease: approach of accelerated treatment based on Adalimumab and antimetabolite therapy

The final results from an international clinical trial involving nearly 2,000 patients with Crohn's disease support the use of a new management strategy referred to as accelerated step-care as a best ... read article

RoActemra approved in European Union to treat children with juvenile idiopathic polyarthritis

Roche has announced that the European Medicines Agency ( EMA ) has approved RoActemra ( Tocilizumab ) to treat children with polyarticular juvenile idiopathic arthritis ( PJIA ), a rare, chronic and d ... read article

Rheumatoid arthritis: fewer discontinuations due to adverse events, serious adverse events, serious infections in patients treated with Abatacept plus Methotrexate

Year 2 data has shown similar efficacy between Abatacept ( Orencia ) plus Methotrexate ( MTX ) and Adalimumab ( Humira ) plus Methotrexate, consistent with the year 1 result which demonstrated compara ... read article

Ustekinumab ( Stelara ), an antibody proven to treat the skin condition psoriasis, has now shown positive results in decreasing the debilitating effects of Crohn’s Disease, according to researchers at ... read article

TNF-alpha blockers: warnings about infection with Legionella and Listeria bacteria

The FDA ( Food and Drug Administration ) has informed healthcare professionals that the Boxed Warning for the entire class of Tumor Necrosis Factor-alpha ( TNF-alpha ) blockers has been updated to inc ... read article

FDA has received reports of malignancies in children using TNF antagonists

The FDA ( Food and Drug Administration ) has received reports of malignancies in children using tumor necrosis factor alpha ( TNF ) blockers, raising concerns of an associated risk and prompting an in ... read article

Risk of tuberculosis with anti-TNF agents

Treatment with anti-tumor necrosis factor ( TNF ) agents is recognized as a risk factor for tuberculosis in patients with immune-mediated inflammatory diseases such as rheumatoid arthritis, ankylosing ... read article

Rheumatoid arthritis: Golimumab shows promising results in patients who have poor response to other TNF-alpha inhibitors

Golimumab ( Simponi ), a new tumour necrosis factor-alpha ( TNF-alpha ) blocker reduces the signs and symptoms of rheumatoid arthritis in patients who have previously received any other TNF-alpha inhi ... read article

Rheumatoid arthritis: treatment with the monoclonal anti-TNF-alpha antibodies Adalimumab and Infliximab linked to increased risk for herpes zoster

Use of monoclonal anti-TNF-alpha antibodies for the treatment of rheumatoid arthritis appears to be associated with an increased risk for herpes zoster. There has been evidence from some studies th ... read article